Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of: * Advanced solid tumor that is no longer responding to therapies OR * Advanced or recurrent endometrial carcinoma OR * Advanced or recurrent ovarian carcinoma OR * Unresectable (Stage IIIB or IV) NSCLC * ECOG Performance Status 0-1 (ECOG status of 2 may be considered following discussion and agreement with sponsor) * Adequate organ and bone marrow function as defined by hematological and serum chemistry limits * At least 18 years old * Both men and women must practice adequate contraception * Informed consent Exclusion Criteria: * Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, AKT, or mTOR inhibitors, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents * Known allergy or hypersensitivity to any of the components of the treatment formulations * Taking oral corticosteroids chronically or \> 1 mg/day warfarin * Not recovered from the toxic effects of prior therapy * History of diabetes mellitus. * Uncontrolled intercurrent illness * Pregnant or breastfeeding * Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study. * HIV positive * Diagnosis of another malignancy may exclude subject from study